A Clinical Study of the ACRYSOF® IQ Extended Depth of Foc... | NCT03274986 | Trialant
NCT03274986
Sponsor
Alcon Research
Status
Completed
Last Update Posted
Apr 7, 2020Actual
Enrollment
242Actual
Phase
Not Applicable
Conditions
Cataract
Interventions
ACRYSOF® IQ Extended Depth of Focus IOL
ACRYSOF® IQ Monofocal IOL
Cataract surgery
Countries
United States
Protocol Section
Identification Module
NCT ID
NCT03274986
Obsolete or Duplicate NCT IDs
Not provided
Organization Study
ILI875-C002
Secondary IDs
Not provided
Brief Title
A Clinical Study of the ACRYSOF® IQ Extended Depth of Focus Intraocular Lens (IOL)
Official Title
A Prospective, Randomized, Controlled, Multi-Center Clinical Study of the ACRYSOF® IQ Extended Depth of Focus IOL
Acronym
Not provided
Organization
Alcon ResearchINDUSTRY
Status Module
Record Verification Date
Mar 2020
Overall Recruitment Status or Expanded Access Status
Completed
Last Known Status
Not provided
Delayed Posting
Not provided
Why Stopped
Not provided
Expanded Access Info
No
Start Date
Oct 11, 2017Actual
Primary Completion Date
Oct 16, 2018Actual
Completion Date
Oct 16, 2018Actual
First Submitted Date
Sep 5, 2017
First Submission Date that Met QC Criteria
Sep 5, 2017
First Posted Date
Sep 7, 2017Actual
Results Waived
Not provided
Results First Submitted Date
Mar 10, 2020
Results First Submitted that Met QC Criteria
Mar 25, 2020
Results First Posted Date
Apr 7, 2020Actual
Certification/Extension (aka Delayed Results) First Submitted Date
Oct 2, 2019
Certification/Extension First Submitted that Passed QC Review
Mar 25, 2020
Certification/Extension First Posted Date
Apr 7, 2020Actual
Last Update Submitted Date
Mar 25, 2020
Last Update Posted Date
Apr 7, 2020Actual
Sponsor/Collaborators Module
Responsible Party, by Official Title
Sponsor
Lead Sponsor
Alcon ResearchINDUSTRY
Collaborators
Not provided
Oversight Module
Has Data Monitoring Committee (DMC)
No
Is FDA Regulated Drug
No
Is FDA Regulated Device
Yes
Is Unapproved Device
Yes
Pediatric Postmarket Surveillance of a Device Product
Not provided
Product Exported from US
Not provided
FDAAA801 Violation
Not provided
Description Module
Brief Summary
The purpose of the study is to demonstrate the safety and performance of ACRYSOF IQ extended depth of focus (EDF) intraocular lens (IOL) at Month 6. Depth of focus (DOF) is the amount of focal plane displacement behind a lens that does not degrade the image quality of a distant object. A larger DOF allows sharp images of closer objects and may provide improved vision at intermediate and near distances.
Detailed Description
Both eyes of a subject must require cataract surgery to qualify for enrollment into this study. Subjects participating in the trial will attend a total of 9 scheduled study visits over a 7-8 month period. Of the 9 visits, 1 is preoperative, 2 are operative, and the remaining 6 are postoperative visits. Primary endpoint data will be collected at the Month 6 (Day 120-180) post second eye implantation visit.
Conditions Module
Conditions
Cataract
Keywords
Not provided
Design Module
Study Type
Interventional
Number of References to an Expanded Access Study
Not provided
Expanded Access Types
Not provided
Patient Registry
Not provided
Target Follow-Up Duration
Not provided
Phases
Not Applicable
Interventional Study Design
Allocation
Biospecimen
No data available
No data is available for this block.
Enrollment
242Actual
Arms/Interventions Module
Arm Groups
Label
Type
Description
Intervention Names
DFT015
Experimental
ACRYSOF® IQ Extended Depth of Focus Intraocular lens (IOL), bilateral implantation
Device: ACRYSOF® IQ Extended Depth of Focus IOL
Procedure: Cataract surgery
SN60WF
Active Comparator
ACRYSOF® IQ Monofocal IOL, bilateral implantation
Device: ACRYSOF® IQ Monofocal IOL
Procedure: Cataract surgery
Interventions
Name
Type
Description
Arm Group Labels
Other Names
ACRYSOF® IQ Extended Depth of Focus IOL
Device
Implantable IOL intending to extend the depth of focus and provide continuous functional vision from distance to near while maintaining distance vision and a visual disturbance profile comparable to a monofocal IOL.
Outcomes Module
Primary Outcomes
Measure
Description
Time Frame
Monocular Photopic Distance Corrected Intermediate Visual Acuity (DCIVA) [(Logarithm of the Minimum Angle of Resolution (logMAR)] 66 Centimeters (cm) From Spectacle Plane
Visual acuity (VA) was tested monocularly (each eye separately) under photopic (well-lit) conditions using best distance correction adjusted for optical infinity, electronic Early Treatment Diabetic Retinopathy Study (ETDRS) charts at a distance of 66 cm from the spectacle plane. DCIVA was measured in logMAR, with 0.02 logMAR increment corresponding to a single letter or 0.1 logMAR increment corresponding to 5 letters, or 1 line, on an ETDRS chart. A lower numeric value represented better VA. This analysis was prespecified for the first operative eye.
Month 6 (120-180 days post second eye implantation)
Monocular Photopic Best Corrected Distance Visual Acuity (BCDVA) logMAR [(4 Meters (m)] From Spectacle Plane
VA was tested monocularly under photopic conditions using the correction obtained from the best correction and no optical infinity adjustment, electronic ETDRS charts at a distance of 4 m from the spectacle plane. VA was measured in logMAR, with 0.02 logMAR increment corresponding to a single letter or 0.1 logMAR increment corresponding to 5 letters, or 1 line, on an ETDRS chart. A lower numeric value represented better VA. This analysis was prespecified for the first operative eye.
Month 6 (120-180 days post second eye implantation)
Monocular Depth of Focus (Measured in the Negative Direction From 0) at 0.20 logMAR From the Mean Defocus Curve
Depth of focus was assessed at 4 meters under photopic (well-lit) conditions using best corrected distance refraction and added defocus. The depth of focus was estimated as the dioptric range between zero defocus and the first point on the negative lens induced mean defocus curve that crosses the 0.2 logMAR using a linear interpolation. A lower numeric value represents better VA. This analysis was pre-specified for the first operative eye. No formal statistical hypothesis testing was planned.
Month 6 (120-180 days post second eye implantation)
Percentage of Eyes Achieving Monocular Photopic DCIVA 0.20 logMAR or Better
Secondary Outcomes
Measure
Description
Time Frame
Monocular Photopic Distance Corrected Near Visual Acuity (DCNVA) (logMAR) 40 cm From Spectacle Plane
VA was tested monocularly under photopic conditions using best distance correction adjusted for optical infinity, electronic ETDRS chart set at 40 cm from the spectacle plane. VA was measured in logMAR, with 0.02 logMAR increment corresponding to a single letter or 0.1 logMAR increment corresponding to 5 letters, or 1 line, on an ETDRS chart. A lower numeric value represented better VA. This analysis was prespecified for the first operative eye.
Other Outcomes
Not provided
Eligibility Module
Eligibility Criteria
Inclusion Criteria:
Best Corrected Distance Visual Acuity (BCDVA) of 0.3 logarithm of the minimum angle of resolution (logMAR) (20/40 Snellen) or worse either with or without a glare source present (e.g., Brightness Acuity Tester)
Preoperative regular astigmatism of < 1.0 D in both eyes
Clear intraocular media other than cataract
Diagnosed with cataract in both eyes
Planned cataract removal by routine small incision surgery
Calculated lens power between 18.0 and 25.0 diopter (D) [when targeted for emmetropia (0.0 D)]
Willing and able to complete all required postoperative visits
Able to comprehend and sign an ethics committee-approved statement of informed consent
Potential postoperative BCDVA of 0.2 logMAR (20/32 Snellen) or better in each eye based on Investigator's medical opinion.
Exclusion Criteria:
History of eye pathology and/or inflammation, as specified in the protocol
Clinically significant/severe ocular surface disease that would affect study measurements based on Investigator expert medical opinion
History of previous intraocular or corneal surgery
Pregnant/lactating or has another condition with associated fluctuation of hormones that could lead to refractive changes
Taking systemic medications that in the Investigator's best medical judgment may confound the outcome or increase the risk to the subject.
McCabe C, Berdahl J, Reiser H, Newsom TH, Cibik L, Koch D, Lemp-Hull J, Jasti S. Clinical outcomes in a U.S. registration study of a new EDOF intraocular lens with a nondiffractive design. J Cataract Refract Surg. 2022 Nov 1;48(11):1297-1304. doi: 10.1097/j.jcrs.0000000000000978. Epub 2022 May 26.
See Also Links
Not provided
Available IPD Information
Not provided
IPD Sharing Statement Module
Plan to Share IPD
No
Description
Not provided
Types
Not provided
Time Frame
Not provided
Access Criteria
Not provided
URL
Not provided
Results Section
Participant Flow Module
Pre-assignment Details
21 subjects discontinued prior to randomization, and 1 subject discontinued after randomization but prior to attempted implantation. This reporting group includes all subjects with attempted implantation, as treated. Note: 1 subject randomized to DFT015 was implanted with SN60WF. Subject withdrew at the 1 month visit.
Recruitment Details
Subjects were recruited from 11 investigative sites located in the United States.
Type of Units Analyzed
Not provided
Arm/Group Information
ID
Title
Description
FG000
DFT015
ACRYSOF® IQ Extended Depth of Focus IOL, bilateral implantation
FG001
SN60WF
ACRYSOF® IQ Monofocal IOL, bilateral implantation
Periods
Title
Milestones
Reasons Not Completed
Overall Study
Type
Comment
Milestone Data
STARTED
All subjects with attempted implantation, as treated.
Baseline Characteristics Module
Baseline Analysis Population Description
Outcome Measures Module
Outcome Measures
Adverse Events Module
Frequency Threshold
5
More Info Module
Limitations and Caveats
Not provided
Annotation Section
No data available
No data is available for this block.
Document Section
Large Document Module
Document Has No Statistical Analysis Plan (SAP)
Not provided
Uploaded Document Information
Type
Includes Protocol
Includes SAP
Includes ICF
Document Label
Document Date
Document Uploaded Date
Document File Name
SAP
No
Yes
No
Statistical Analysis Plan
Feb 12, 2018
Oct 30, 2019
Derived Section
Miscellaneous Info Module
Version Holder
Jul 10, 2026
Removed Countries
Not provided
Submission Tracking
Estimated Results First Submitted Date
Not provided
Condition Browse Module
MeSH Terms
Intervention Browse Module
MeSH Terms
Randomized
Intervention Model
Parallel Assignment
Intervention Model Description
Not provided
Primary Purpose
Treatment
Observational Model
Not provided
Time Perspective
Not provided
Masking Info
Masking
Double
Masking Description
Not provided
Who Masked
ParticipantOutcomes Assessor
DFT015
Model DFT015
ACRYSOF® IQ Monofocal IOL
Device
Monofocal IOL implanted for long-term use over the lifetime of the pseudophakic subject
SN60WF
Model SN60WF
Cataract surgery
Procedure
IOL bilateral implantation
DFT015
SN60WF
VA was tested monocularly under photopic conditions using best distance correction adjusted for optical infinity, electronic ETDRS charts at a distance of 66 cm from the eye. DCIVA was measured in logMAR, with 0.02 logMAR increment corresponding to a single letter or 0.1 logMAR increment corresponding to 5 letters, or 1 line, on an ETDRS chart. A lower numeric value represented better VA. This analysis was prespecified for the first operative eye. No formal statistical hypothesis testing was planned.
Month 6 (120-180 days post second eye implantation)
Percentage of Subjects With Ocular Adverse Events
An adverse event (AE) was defined as any untoward medical occurrence, unintended disease or injury, or untoward clinical signs (including abnormal laboratory findings) in subjects, users or other persons, whether or not related to the investigational medical device (test article). Ocular AEs are events localized to the eye. Cumulative and persistent serious adverse events as defined in ISO 11979-7:2014 were collected. This outcome measure was prespecified for the Model DFT015 first and second eyes. No formal statistical hypothesis testing was planned.
Day 0 (first operative eye visit), up to Month 6 (120-180 days post second eye implantation)
Mesopic Contrast Sensitivity
Contrast sensitivity (i.e., the ability to detect objects by distinguishing them from their background) was assessed monocularly with the subject's best spectacle correction under mesopic (low, but not quite dark) conditions at a distance of 8 (2.45 m) feet from the eye at a spatial frequency of 1.5, 3, 6, and 12 cycles per degree (cpd) using the Vector Vision CSV 1000-HGT with and without a glare source. Raw scores from contrast sensitivity testing were transformed to log units. A higher numeric value represented better contrast sensitivity. This analysis was prespecified for the first operative eye. No formal statistical hypothesis testing was planned.
Month 6 (120-180 days post second eye implantation)
Month 6 (120-180 days post second eye implantation)
Percentage of Subjects Who Respond "Never" to Question 1 of the Intraocular Lens Satisfaction (IOLSAT) Questionnaire: "Overall, in the Past 7 Days, How Often Did You Need to Wear Eyeglasses to See?"
The IOLSAT questionnaire assessed the subjective quality of vision with respect to need for spectacles, as well as the subject's expectation and satisfaction with their quality of vision at 6 months. Results are reported consistent with multiple testing strategy.
Month 6 (120-180 days post second eye implantation)
Monocular Photopic Uncorrected Intermediate Visual Acuity (UCIVA) (logMAR) 66 cm From Spectacle Plane
VA was tested monocularly under photopic conditions with no refractive correction or adjustment for optical infinity, using electronic ETDRS charts at a distance of 66 cm from the spectacle plane. UCIVA was measured in logMAR, with 0.02 logMAR increment corresponding to a single letter or 0.1 logMAR increment corresponding to 5 letters, or 1 line, on an ETDRS chart. A lower numeric value represented better VA. This analysis was prespecified for the first operative eye. No formal statistical hypothesis testing was planned.
Month 6 (120-180 days post second eye implantation)
VA was tested monocularly under photopic conditions without refractive correction but with adjustment for optical infinity, electronic ETDRS charts at a distance of 4 m from the eye. +0.25 D spherical power was applied to correct for optical infinity. UCDVA was measured in logMAR, with 0.02 logMAR increment corresponding to a single letter or 0.1 logMAR increment corresponding to 5 letters, or 1 line, on an ETDRS chart. A lower numeric value represented better VA.This analysis was prespecified for the first operative eye. No formal statistical hypothesis testing was planned.
Month 6 (120-180 days post second eye implantation)
Percentage of Subjects With Visual Disturbances as Reported by the Subjects Using the Questionnaire for Visual Disturbances (QUVID)
Rates of severe and most bothersome visual disturbances as reported by the subjects on the QUVID questionnaire, a Patient Reported Outcome (PRO) questionnaire. No formal statistical hypothesis testing was planned.
Month 6 (120-180 days post second eye implantation)
Fort Collins
Colorado
80528
United States
Alcon Investigative Site
Bradenton
Florida
34209
United States
Alcon Investigative Site
Sebring
Florida
33870
United States
Alcon Investigative Site
Gainesville
Georgia
30501
United States
Alcon Investigative Site
Rock Island
Illinois
61201
United States
Alcon Investigative Site
Cincinnati
Ohio
45242
United States
Alcon Investigative Site
Allenwood
Pennsylvania
17810
United States
Alcon Investigative Site
Kingston
Pennsylvania
18704
United States
Alcon Investigative Site
West Mifflin
Pennsylvania
15122
United States
Alcon Investigative Site
Sioux Falls
South Dakota
57108
United States
FG000107 subjects
FG001113 subjects
Successful Implantation, as Treated
FG000107 subjects
FG001113 subjects
COMPLETED
FG000107 subjects
FG001111 subjects
NOT COMPLETED
FG0000 subjects
FG0012 subjects
Type
Comment
Reasons
Withdrawal by Subject
FG0000 subjects
FG0011 subjects
Lost to Follow-up
FG0000 subjects
FG0011 subjects
This analysis population included all randomized eyes with successful IOL implantation (All-Implanted Analysis Set), as treated.
Type of Units Analyzed
Not provided
Arm/Group Information
ID
Title
Description
BG000
DFT015
ACRYSOF® IQ Extended Depth of Focus IOL, bilateral implantation
BG001
SN60WF
ACRYSOF® IQ Monofocal IOL, bilateral implantation
BG002
Total
Total of all reporting groups
Denominators
Units
Counts
Participants
BG000107
BG001113
BG002220
Baseline Measures
Title
Description
Population Description
Parameter Type
Dispersion Type
Unit of Measure
Calculate Percentage
Denominator Units Selected
Denominators
Classes
Age, Continuous
Mean
Standard Deviation
years
Title
Denominators
Categories
Title
Measurements
BG00068.8± 7.82
BG00168.8± 6.63
BG00268.8± 7.22
Sex: Female, Male
Count of Participants
Participants
Title
Denominators
Categories
Title
Measurements
Female
BG00059
BG00164
BG002
Ethnicity (NIH/OMB)
Count of Participants
Participants
Title
Denominators
Categories
Title
Measurements
Hispanic or Latino
BG0002
BG0012
BG002
Race (NIH/OMB)
Count of Participants
Participants
Title
Denominators
Categories
Title
Measurements
American Indian or Alaska Native
BG0000
BG0011
BG002
Type
Title
Description
Population Description
Reporting Status
Anticipated Posting Date
Parameter Type
Dispersion Type
Unit of Measure
Calculate Percentage
Time Frame
Units Analyzed
Denominator Units Selected
Arm/Group Information
Denominators
Classes
Analyses
Primary
Monocular Photopic Distance Corrected Intermediate Visual Acuity (DCIVA) [(Logarithm of the Minimum Angle of Resolution (logMAR)] 66 Centimeters (cm) From Spectacle Plane
Visual acuity (VA) was tested monocularly (each eye separately) under photopic (well-lit) conditions using best distance correction adjusted for optical infinity, electronic Early Treatment Diabetic Retinopathy Study (ETDRS) charts at a distance of 66 cm from the spectacle plane. DCIVA was measured in logMAR, with 0.02 logMAR increment corresponding to a single letter or 0.1 logMAR increment corresponding to 5 letters, or 1 line, on an ETDRS chart. A lower numeric value represented better VA. This analysis was prespecified for the first operative eye.
All-Implanted Analysis Set, as treated
Posted
Least Squares Mean
Standard Error
logMAR
Month 6 (120-180 days post second eye implantation)
Eyes
Eyes
ID
Title
Description
OG000
DFT015
ACRYSOF® IQ Extended Depth of Focus IOL, bilateral implantation
OG001
SN60WF
ACRYSOF® IQ Monofocal IOL, bilateral implantation
Units
Counts
Participants
OG000107
OG001111
Eyes
OG000107
OG001
Title
Denominators
Categories
Title
Measurements
OG0000.148± 0.0120
OG0010.312± 0.0118
Group IDs
Group Description
Statistical Method
Statistical Comment
P-Value
P-Value Comment
Parameter Type
Parameter Value
Dispersion Type
Dispersion Value
Confidence Interval Sides
Confidence Interval %
CI Lower Limit
CI Upper Limit
CI Lower Limit Comment
CI Upper Limit Comment
Estimate Comment
Tested Non-Inferiority
Non-Inferiority Type
Non-Inferiority Comment
Other Analysis Description
OG000
OG001
t-test, 2 sided
<0.001
2-sided p-value reported. A hypothesis test was based on a two sample t-test, with a type I error rate of 0.025, 1-sided.
Least Squares Mean Difference
-0.164
Standard Error of the Mean
0.0168
2-Sided
95
-0.197
-0.131
Least squares mean difference (DFT015 - SN60WF)
Superiority
Primary
Monocular Photopic Best Corrected Distance Visual Acuity (BCDVA) logMAR [(4 Meters (m)] From Spectacle Plane
VA was tested monocularly under photopic conditions using the correction obtained from the best correction and no optical infinity adjustment, electronic ETDRS charts at a distance of 4 m from the spectacle plane. VA was measured in logMAR, with 0.02 logMAR increment corresponding to a single letter or 0.1 logMAR increment corresponding to 5 letters, or 1 line, on an ETDRS chart. A lower numeric value represented better VA. This analysis was prespecified for the first operative eye.
All-Implanted Analysis Set, as treated
Posted
Least Squares Mean
Standard Error
logMAR
Month 6 (120-180 days post second eye implantation)
Eyes
Eyes
ID
Title
Description
OG000
DFT015
ACRYSOF® IQ Extended Depth of Focus IOL, bilateral implantation
OG001
SN60WF
ACRYSOF® IQ Monofocal IOL, bilateral implantation
Units
Counts
Participants
Primary
Monocular Depth of Focus (Measured in the Negative Direction From 0) at 0.20 logMAR From the Mean Defocus Curve
Depth of focus was assessed at 4 meters under photopic (well-lit) conditions using best corrected distance refraction and added defocus. The depth of focus was estimated as the dioptric range between zero defocus and the first point on the negative lens induced mean defocus curve that crosses the 0.2 logMAR using a linear interpolation. A lower numeric value represents better VA. This analysis was pre-specified for the first operative eye. No formal statistical hypothesis testing was planned.
All-Implanted Analysis Set, as treated. Number analyzed is the number of subjects/eyes with data available for analysis at specified defocus.
Posted
Number
diopter
Month 6 (120-180 days post second eye implantation)
Eyes
Eyes
ID
Title
Description
OG000
DFT015
ACRYSOF® IQ Extended Depth of Focus IOL, bilateral implantation
OG001
SN60WF
ACRYSOF® IQ Monofocal IOL, bilateral implantation
Units
Counts
Participants
Primary
Percentage of Eyes Achieving Monocular Photopic DCIVA 0.20 logMAR or Better
VA was tested monocularly under photopic conditions using best distance correction adjusted for optical infinity, electronic ETDRS charts at a distance of 66 cm from the eye. DCIVA was measured in logMAR, with 0.02 logMAR increment corresponding to a single letter or 0.1 logMAR increment corresponding to 5 letters, or 1 line, on an ETDRS chart. A lower numeric value represented better VA. This analysis was prespecified for the first operative eye. No formal statistical hypothesis testing was planned.
All-Implanted Analysis Set, as treated.
Posted
Number
percentage of eyes
Month 6 (120-180 days post second eye implantation)
Eyes
Eyes
ID
Title
Description
OG000
DFT015
ACRYSOF® IQ Extended Depth of Focus IOL, bilateral implantation
OG001
SN60WF
ACRYSOF® IQ Monofocal IOL, bilateral implantation
Units
Counts
Participants
OG000
Primary
Percentage of Subjects With Ocular Adverse Events
An adverse event (AE) was defined as any untoward medical occurrence, unintended disease or injury, or untoward clinical signs (including abnormal laboratory findings) in subjects, users or other persons, whether or not related to the investigational medical device (test article). Ocular AEs are events localized to the eye. Cumulative and persistent serious adverse events as defined in ISO 11979-7:2014 were collected. This outcome measure was prespecified for the Model DFT015 first and second eyes. No formal statistical hypothesis testing was planned.
This analysis population included all eyes with attempted IOL implantation (successful or aborted after contact with the eye) (Safety Analysis Set).
Posted
Number
percentage of subjects
Day 0 (first operative eye visit), up to Month 6 (120-180 days post second eye implantation)
Eyes
Eyes
ID
Title
Description
OG000
DFT015 First Eye
All eyes with attempted test article implantation (successful or aborted after contact with the eye) in the first implanted eye
OG001
DFT015 Second Eye
All eyes with attempted test article implantation (successful or aborted after contact with the eye) in the second implanted eye
Primary
Mesopic Contrast Sensitivity
Contrast sensitivity (i.e., the ability to detect objects by distinguishing them from their background) was assessed monocularly with the subject's best spectacle correction under mesopic (low, but not quite dark) conditions at a distance of 8 (2.45 m) feet from the eye at a spatial frequency of 1.5, 3, 6, and 12 cycles per degree (cpd) using the Vector Vision CSV 1000-HGT with and without a glare source. Raw scores from contrast sensitivity testing were transformed to log units. A higher numeric value represented better contrast sensitivity. This analysis was prespecified for the first operative eye. No formal statistical hypothesis testing was planned.
Safety Analysis Set. Number analyzed is the number of subjects/eyes with data available for analysis at without glare and with glare assessments.
Posted
Mean
Standard Deviation
log unit
Month 6 (120-180 days post second eye implantation)
Eyes
Eyes
ID
Title
Description
OG000
DFT015
ACRYSOF® IQ Extended Depth of Focus IOL, bilateral implantation
OG001
SN60WF
ACRYSOF® IQ Monofocal IOL, bilateral implantation
Units
Counts
Participants
Secondary
Monocular Photopic Distance Corrected Near Visual Acuity (DCNVA) (logMAR) 40 cm From Spectacle Plane
VA was tested monocularly under photopic conditions using best distance correction adjusted for optical infinity, electronic ETDRS chart set at 40 cm from the spectacle plane. VA was measured in logMAR, with 0.02 logMAR increment corresponding to a single letter or 0.1 logMAR increment corresponding to 5 letters, or 1 line, on an ETDRS chart. A lower numeric value represented better VA. This analysis was prespecified for the first operative eye.
All-Implanted Analysis Set, as treated.
Posted
Least Squares Mean
Standard Error
logMAR
Month 6 (120-180 days post second eye implantation)
Eyes
Eyes
ID
Title
Description
OG000
DFT015
ACRYSOF® IQ Extended Depth of Focus IOL, bilateral implantation
OG001
SN60WF
ACRYSOF® IQ Monofocal IOL, bilateral implantation
Units
Counts
Participants
OG000
Secondary
Percentage of Subjects Who Respond "Never" to Question 1 of the Intraocular Lens Satisfaction (IOLSAT) Questionnaire: "Overall, in the Past 7 Days, How Often Did You Need to Wear Eyeglasses to See?"
The IOLSAT questionnaire assessed the subjective quality of vision with respect to need for spectacles, as well as the subject's expectation and satisfaction with their quality of vision at 6 months. Results are reported consistent with multiple testing strategy.
All-Implanted Analysis Set, as treated.
Posted
Number
percentage of subjects
Month 6 (120-180 days post second eye implantation)
ID
Title
Description
OG000
DFT015
ACRYSOF® IQ Extended Depth of Focus IOL, bilateral implantation
OG001
SN60WF
ACRYSOF® IQ Monofocal IOL, bilateral implantation
Units
Counts
Participants
OG000
Secondary
Monocular Photopic Uncorrected Intermediate Visual Acuity (UCIVA) (logMAR) 66 cm From Spectacle Plane
VA was tested monocularly under photopic conditions with no refractive correction or adjustment for optical infinity, using electronic ETDRS charts at a distance of 66 cm from the spectacle plane. UCIVA was measured in logMAR, with 0.02 logMAR increment corresponding to a single letter or 0.1 logMAR increment corresponding to 5 letters, or 1 line, on an ETDRS chart. A lower numeric value represented better VA. This analysis was prespecified for the first operative eye. No formal statistical hypothesis testing was planned.
All-Implanted Analysis Set, as treated.
Posted
Mean
Standard Deviation
logMAR
Month 6 (120-180 days post second eye implantation)
Eyes
Eyes
ID
Title
Description
OG000
DFT015
ACRYSOF® IQ Extended Depth of Focus IOL, bilateral implantation
VA was tested monocularly under photopic conditions without refractive correction but with adjustment for optical infinity, electronic ETDRS charts at a distance of 4 m from the eye. +0.25 D spherical power was applied to correct for optical infinity. UCDVA was measured in logMAR, with 0.02 logMAR increment corresponding to a single letter or 0.1 logMAR increment corresponding to 5 letters, or 1 line, on an ETDRS chart. A lower numeric value represented better VA.This analysis was prespecified for the first operative eye. No formal statistical hypothesis testing was planned.
All-Implanted Analysis Set, as treated.
Posted
Mean
Standard Deviation
logMAR
Month 6 (120-180 days post second eye implantation)
Eyes
Eyes
ID
Title
Description
OG000
DFT015
ACRYSOF® IQ Extended Depth of Focus IOL, bilateral implantation
OG001
SN60WF
ACRYSOF® IQ Monofocal IOL, bilateral implantation
Units
Counts
Participants
Secondary
Percentage of Subjects With Visual Disturbances as Reported by the Subjects Using the Questionnaire for Visual Disturbances (QUVID)
Rates of severe and most bothersome visual disturbances as reported by the subjects on the QUVID questionnaire, a Patient Reported Outcome (PRO) questionnaire. No formal statistical hypothesis testing was planned.
Safety Analysis Set. Number analyzed is the number of subjects/eyes with data available for analysis at specified visual disturbances.
Posted
Number
percentage of subjects
Month 6 (120-180 days post second eye implantation)
ID
Title
Description
OG000
DFT015
ACRYSOF® IQ Extended Depth of Focus IOL, bilateral implantation
OG001
SN60WF
ACRYSOF® IQ Monofocal IOL, bilateral implantation
Units
Counts
Participants
OG000
Time Frame
Pre-operation (Day -28) up to Day 120-180 (post second eye implantation), up to 8 months
Description
An AE was any untoward medical occurrence, unintended disease or injury, or untoward clinical signs in subjects, users or other persons, whether or not related to the investigational medical device. AEs were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator. Safety Analysis Set. "At Risk" population of preoperative and systemic AEs is reported in units of subjects; all other AE populations are reported in units of eyes.
All-Cause Mortality Comment
Not provided
Arm/Groups
ID
Title
Description
Deaths (Affected)
Deaths (At Risk)
Serious Events (Affected)
Serious Events (At Risk)
Other Events (Affected)
Other Events (At Risk)
EG000
Preoperative
All subjects in the safety analysis set prior to initiation of treatment
0
220
0
220
0
220
EG001
DFT015 First Eye
All eyes with attempted test article implantation (successful or aborted after contact with the eye) in the first implanted eye
0
107
3
107
5
107
EG002
DFT015 Second Eye
All eyes with attempted test article implantation (successful or aborted after contact with the eye) in the second implanted eye
0
106
2
106
6
106
EG003
DFT015 Systemic
All subjects with attempted test article implantation (successful or aborted after contact with the eye)
0
107
7
107
0
107
EG004
SN60WF First Eye
All eyes with attempted control article implantation (successful or aborted after contact with the eye) in the first implanted eye
0
113
3
113
9
113
EG005
SN60WF Second Eye
All eyes with attempted control article implantation (successful or aborted after contact with the eye) in the second implanted eye
0
113
1
113
8
113
EG006
SN60WF Systemic
All subjects with attempted control article implantation (successful or aborted after contact with the eye)
0
113
4
113
0
113
Serious Adverse Events
Term
Organ System
Source Vocabulary
Assessment Type
Notes
Statistical Information
Coronary artery disease
Cardiac disorders
MedDRA (20.0)
Systematic Assessment
EG0000 affected220 at risk
EG0010 affected107 at risk
EG0020 affected106 at risk
EG0030 affected107 at risk
EG0040 affected113 at risk
EG0050 affected113 at risk
EG0061 affected113 at risk
Heart valve incompetence
Cardiac disorders
MedDRA (20.0)
Systematic Assessment
EG0000 affected220 at risk
EG0010 affected107 at risk
EG0020 affected106 at risk
EG003
Cystoid macular oedema
Eye disorders
MedDRA (20.0)
Systematic Assessment
EG0000 affected220 at risk
EG0011 affected107 at risk
EG0020 affected106 at risk
EG003
Photopsia
Eye disorders
MedDRA (20.0)
Systematic Assessment
EG0000 affected220 at risk
EG0010 affected107 at risk
EG0020 affected106 at risk
EG003
Retinal detachment
Eye disorders
MedDRA (20.0)
Systematic Assessment
EG0000 affected220 at risk
EG0010 affected107 at risk
EG0020 affected106 at risk
EG003
Peptic ulcer
Gastrointestinal disorders
MedDRA (20.0)
Systematic Assessment
EG0000 affected220 at risk
EG0010 affected107 at risk
EG0020 affected106 at risk
EG003
Ulcer haemorrhage
General disorders
MedDRA (20.0)
Systematic Assessment
EG0000 affected220 at risk
EG0010 affected107 at risk
EG0020 affected106 at risk
EG003
Cholelithiasis
Hepatobiliary disorders
MedDRA (20.0)
Systematic Assessment
EG0000 affected220 at risk
EG0010 affected107 at risk
EG0020 affected106 at risk
EG003
Abdominal abscess
Infections and infestations
MedDRA (20.0)
Systematic Assessment
EG0000 affected220 at risk
EG0010 affected107 at risk
EG0020 affected106 at risk
EG003
Pneumonia
Infections and infestations
MedDRA (20.0)
Systematic Assessment
EG0000 affected220 at risk
EG0010 affected107 at risk
EG0020 affected106 at risk
EG003
Bladder injury
Injury, poisoning and procedural complications
MedDRA (20.0)
Systematic Assessment
EG0000 affected220 at risk
EG0010 affected107 at risk
EG0020 affected106 at risk
EG003
Cataract operation complication
Injury, poisoning and procedural complications
MedDRA (20.0)
Systematic Assessment
EG0000 affected220 at risk
EG0010 affected107 at risk
EG0022 affected106 at risk
EG003
Femoral neck fracture
Injury, poisoning and procedural complications
MedDRA (20.0)
Systematic Assessment
EG0000 affected220 at risk
EG0010 affected107 at risk
EG0020 affected106 at risk
EG003
Post procedural bile leak
Injury, poisoning and procedural complications
MedDRA (20.0)
Systematic Assessment
EG0000 affected220 at risk
EG0010 affected107 at risk
EG0020 affected106 at risk
EG003
Spinal fracture
Injury, poisoning and procedural complications
MedDRA (20.0)
Systematic Assessment
EG0000 affected220 at risk
EG0010 affected107 at risk
EG0020 affected106 at risk
EG003
Surgical procedure repeated
Injury, poisoning and procedural complications
MedDRA (20.0)
Systematic Assessment
EG0000 affected220 at risk
EG0010 affected107 at risk
EG0022 affected106 at risk
EG003
Breast cancer
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
MedDRA (20.0)
Systematic Assessment
EG0000 affected220 at risk
EG0010 affected107 at risk
EG0020 affected106 at risk
EG003
Panic attack
Psychiatric disorders
MedDRA (20.0)
Systematic Assessment
EG0000 affected220 at risk
EG0010 affected107 at risk
EG0020 affected106 at risk
EG003
Chronic obstructive pulmonary disease
Respiratory, thoracic and mediastinal disorders
MedDRA (20.0)
Systematic Assessment
EG0000 affected220 at risk
EG0010 affected107 at risk
EG0020 affected106 at risk
EG003
Aneurysm repair
Surgical and medical procedures
MedDRA (20.0)
Systematic Assessment
EG0000 affected220 at risk
EG0010 affected107 at risk
EG0020 affected106 at risk
EG003
Lens extraction
Surgical and medical procedures
MedDRA (20.0)
Systematic Assessment
EG0000 affected220 at risk
EG0010 affected107 at risk
EG0020 affected106 at risk
EG003
Vitrectomy
Surgical and medical procedures
MedDRA (20.0)
Systematic Assessment
EG0000 affected220 at risk
EG0010 affected107 at risk
EG0020 affected106 at risk
EG003
Hyphaema
Eye disorders
MedDRA (20.0)
Systematic Assessment
EG0000 affected220 at risk
EG0011 affected107 at risk
EG0020 affected106 at risk
EG003
Transient ischaemic attack
Nervous system disorders
MedDRA (20.0)
Systematic Assessment
EG0000 affected220 at risk
EG0011 affected107 at risk
EG0020 affected106 at risk
EG003
Other Adverse Events
Term
Organ System
Source Vocabulary
Assessment Type
Notes
Statistical Information
Posterior capsule opacification
Eye disorders
MedDRA (20.0)
Systematic Assessment
EG0000 affected220 at risk
EG0015 affected107 at risk
EG0026 affected106 at risk
EG0030 affected107 at risk
EG0049 affected113 at risk
EG0058 affected113 at risk
EG0060 affected113 at risk
Certain Agreements
Are all PI(s) employees of the sponsor?
No
Restriction Type
OTHER
Results Disclosure Restriction on PI(s)?
Yes
Other Details
Sponsor reserves the right of prior review of any publication or presentation of information related to the study.